Cubist Systematic Strategies LLC grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 3,269.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 384,076 shares of the biotechnology company's stock after acquiring an additional 372,676 shares during the quarter. Cubist Systematic Strategies LLC owned 0.16% of ADMA Biologics worth $6,587,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Perpetual Ltd acquired a new stake in ADMA Biologics during the 4th quarter worth approximately $62,300,000. Allspring Global Investments Holdings LLC raised its position in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. B Group Inc. purchased a new position in ADMA Biologics in the 4th quarter worth approximately $39,231,000. Raymond James Financial Inc. purchased a new position in ADMA Biologics during the 4th quarter valued at $19,076,000. Finally, Principal Financial Group Inc. increased its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after acquiring an additional 1,059,394 shares in the last quarter. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Price Performance
Shares of NASDAQ:ADMA traded up $0.47 during midday trading on Monday, hitting $20.45. 4,580,765 shares of the stock were exchanged, compared to its average volume of 3,721,644. The company has a 50 day moving average price of $20.23 and a 200-day moving average price of $18.76. ADMA Biologics, Inc. has a twelve month low of $8.42 and a twelve month high of $25.67. The stock has a market cap of $4.86 billion, a P/E ratio of 73.04 and a beta of 0.57. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm's revenue was up 40.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 EPS. On average, research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Raymond James upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday. StockNews.com downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ADMA Biologics has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.
Get Our Latest Research Report on ADMA
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
